But microdosing GLP-1s is not an established dementia-prevention strategy
Ultimately, 300 were excluded for the following reasons: duration of intervention less than 40 weeks (n=102), absence of obesity-specific outcomes (n=81), use of animal or in vitro models (n=58), and lack of relevant comparator arms (n=59)
Using both SGLT-2 and DPP-4 inhibitors as active comparators strengthened study validity, while register linkage minimized selection and recall bias by ensuring exposures were recorded independently of outcomes
If we dont deal with the problem, then were just amplifying the yo-yo thats been here for many years losing weight, regaining it, says Wyatt, coauthor of Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight
One type of oral medication, metformin, is the go-to medication for treating T2D